BACKGROUND AND AIM: Diabetes is associated with left ventricular hypertrophy (LVH) and impaired systolic function in hypertensive patients, but less is known about its impact on LVH regression and functional improvement during antihypertensive treatment. METHODS AND RESULTS: We performed annual echocardiography in 730 non-diabetic and 93 diabetic patients (aged 55-80 years) with hypertension and electrocardiographic LVH during 4.8-year losartan- or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Baseline mean blood pressure (BP) and LV mass did not differ between groups. Diabetic patients had higher body mass index and pulse pressure, and lower LV ejection fraction, midwall shortening, stress-corrected midwall shortening, and estimated glomerular filtration rate (all p<0.05), and were more likely to have albuminuria. Despite comparable BP reduction in diabetic and non-diabetic groups during treatment (33/18 vs. 28/16mmHg (ns)), diabetes was associated with higher prevalence of persistent LVH (47 vs. 39%, p<0.05). In multivariate analyses, diabetes independently predicted less LV mass reduction and less improvement in stress-corrected LV midwall shortening (both p<0.01). CONCLUSION: Among hypertensive patients with LVH, diabetes is associated with more residual LVH and less improvement in systolic LV function by echocardiography over 4.8 years of antihypertensive treatment.
BACKGROUND AND AIM: Diabetes is associated with left ventricular hypertrophy (LVH) and impaired systolic function in hypertensivepatients, but less is known about its impact on LVH regression and functional improvement during antihypertensive treatment. METHODS AND RESULTS: We performed annual echocardiography in 730 non-diabetic and 93 diabeticpatients (aged 55-80 years) with hypertension and electrocardiographic LVH during 4.8-year losartan- or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Baseline mean blood pressure (BP) and LV mass did not differ between groups. Diabeticpatients had higher body mass index and pulse pressure, and lower LV ejection fraction, midwall shortening, stress-corrected midwall shortening, and estimated glomerular filtration rate (all p<0.05), and were more likely to have albuminuria. Despite comparable BP reduction in diabetic and non-diabetic groups during treatment (33/18 vs. 28/16mmHg (ns)), diabetes was associated with higher prevalence of persistent LVH (47 vs. 39%, p<0.05). In multivariate analyses, diabetes independently predicted less LV mass reduction and less improvement in stress-corrected LV midwall shortening (both p<0.01). CONCLUSION: Among hypertensivepatients with LVH, diabetes is associated with more residual LVH and less improvement in systolic LV function by echocardiography over 4.8 years of antihypertensive treatment.
Authors: Brian R Lindman; Suzanne V Arnold; José A Madrazo; Alan Zajarias; Stephanie N Johnson; Julio E Pérez; Douglas L Mann Journal: Circ Heart Fail Date: 2011-02-25 Impact factor: 8.790
Authors: Bernhard M Kaess; Philimon Gona; Martin G Larson; Susan Cheng; Jayashree Aragam; Satish Kenchaiah; Emelia J Benjamin; Ramachandran S Vasan Journal: Heart Date: 2013-09-16 Impact factor: 5.994
Authors: Luca Faconti; Charlotte Elizabeth Mills; Virginia Govoni; Haotian Gu; Steven Morant; Benju Jiang; J Kennedy Cruickshank; Andrew James Webb Journal: Br J Clin Pharmacol Date: 2018-11-13 Impact factor: 4.335
Authors: Henrik Reinhard; Peter R Hansen; Niels Wiinberg; Andreas Kjær; Claus L Petersen; Kaj Winther; Hans-Henrik Parving; Peter Rossing; Peter K Jacobsen Journal: Cardiovasc Diabetol Date: 2012-03-05 Impact factor: 9.951
Authors: Kristofer T Michalson; Leanne Groban; Timothy D Howard; Carol A Shively; Areepan Sophonsritsuk; Susan E Appt; J Mark Cline; Thomas B Clarkson; J Jeffrey Carr; Dalane W Kitzman; Thomas C Register Journal: J Am Heart Assoc Date: 2018-11-06 Impact factor: 5.501